Filing Flows › Fennec Pharmaceuticals (FENC) › Q2 2026
Fennec Pharmaceuticals (FENC) Q2 2026 earnings results (second quarter 2026)
10-Q filed Aug 13, 2026
Fennec Pharmaceuticals (FENC) reported revenue of $17.9M for the second quarter 2026 (Q2 2026), +85% from a year earlier and +18% from the quarter before. Operating margin was 9.7%, net earnings $2.0M (11.0% of revenue).
Fennec Pharmaceuticals, Q2 2026: revenue $17.9M (+85% year over year), operating margin 9.7%, net earnings $2.0M, operating cash flow $50K. The chart follows the revenue to costs, profit and cash.
| Q2 2026 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $17.9M | +18% | +85% |
| Operating profit | $1.7M | — | — |
| Net earnings | $2.0M | +882% | — |
| Operating cash flow | $50K | -98% | — |
What changed
Revenue was $17.9M in Q2 2026, up 85% year over year and up 18% from the previous quarter. PEDMARK product sales, net was the largest line at 96% of revenue. PEDMARK product sales, net added $7.5M year over year (up 78%), 91% of the total change.
Operating profit was $1.7M, a 9.7% margin (up 38.0 points year over year). Total costs grew 30% against revenue growth of 85%. The fastest-growing cost line was Sales & marketing (+123%). Net earnings were $2.0M. The effective tax rate was 2.1%.
Operating cash flow was $50K, 3% of net earnings. Non-cash charges added back $1.8M of share-based compensation. Working capital and other items used $3.7M.
Questions
What was Fennec Pharmaceuticals' revenue in the second quarter 2026?
Fennec Pharmaceuticals (FENC) reported revenue of $17.9M for the second quarter 2026 (Q2 2026), +85% from a year earlier and +18% from the quarter before.
Was Fennec Pharmaceuticals profitable in the second quarter 2026?
Operating profit was $1.7M (9.7% of revenue) and net earnings $2.0M.